Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Short Interest Up 1,180.7% in January

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) saw a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 2,710,000 shares, an increase of 1,180.7% from the January 15th total of 211,600 shares. Based on an average daily volume of 17,180,000 shares, the days-to-cover ratio is currently 0.2 days. Approximately 25.5% of the company’s stock are sold short.

Institutional Investors Weigh In On Hepion Pharmaceuticals

An institutional investor recently bought a new position in Hepion Pharmaceuticals stock. Anson Funds Management LP acquired a new position in Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 231,849 shares of the company’s stock, valued at approximately $155,000. Anson Funds Management LP owned approximately 3.33% of Hepion Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). 17.24% of the stock is owned by hedge funds and other institutional investors.

Hepion Pharmaceuticals Trading Down 6.2 %

Hepion Pharmaceuticals stock traded down $0.01 on Friday, reaching $0.19. 4,245,096 shares of the stock were exchanged, compared to its average volume of 39,302,922. The stock has a market cap of $1.32 million, a PE ratio of -0.04 and a beta of 1.65. The firm has a fifty day moving average price of $0.41 and a two-hundred day moving average price of $0.59. Hepion Pharmaceuticals has a twelve month low of $0.12 and a twelve month high of $3.49.

Hepion Pharmaceuticals Company Profile

Hepion Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms.